AstraZeneca chair buys 2,500 shares at £121
AstraZeneca’s Non-Executive Chair Michel Demaré reported a market purchase of 2,500 ordinary shares on September 14, 2026.
Rhea-AI Filing Summary
AstraZeneca PLC (AZN) reports that Non-Executive Chair of the Board Michel Demaré purchased AstraZeneca ordinary shares. On September 14, 2026, he acquired 2,500 Ordinary Shares of US$0.25 nominal value each at a price of £121.213296 per share on the London market.
The notification is made as a Director/Person Discharging Managerial Responsibilities (PDMR) transaction in accordance with the EU Market Abuse Regulation as it forms part of UK law.
Positive
- None.
Negative
- None.
Key Figures
Shares purchased: 2,500 shares
Purchase price per share: £121.213296 per share
Transaction date: September 14, 2026
3 metrics
Shares purchased
2,500 shares
Ordinary Shares of US$0.25 each bought by Michel Demaré on September 14, 2026
Purchase price per share
£121.213296 per share
Price paid for AstraZeneca Ordinary Shares on September 14, 2026
Transaction date
September 14, 2026
Date of Michel Demaré’s purchase of AstraZeneca Ordinary Shares
Key Terms
Person Discharging Managerial Responsibilities, EU Market Abuse Regulation, LEI
3 terms
Person Discharging Managerial Responsibilities regulatory
"Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC"
A person discharging managerial responsibilities is an individual who holds a senior role with authority to make or influence a company’s strategic or operational decisions, such as executives, board members, or other top managers. Investors care because these people often have access to confidential information and their buying or selling of company shares must be disclosed—like a referee who knows the score before the crowd, their actions can signal important, non-public insights about a company's prospects.
EU Market Abuse Regulation regulatory
"made in accordance with the requirements of the EU Market Abuse Regulation"
A set of EU-wide rules that prevent cheating in financial markets by banning insider trading, market manipulation, and misleading disclosure; it also requires timely public release of key company information so everyone can play on a level field. For investors, it reduces the risk that prices are driven by secret deals or false signals, making markets fairer and more reliable for deciding when to buy or sell — like referees enforcing fair play in a game.
LEI financial
"LEI | PY6ZZQWO2IZFZC3IOL08"
A Legal Entity Identifier (LEI) is a unique 20-character code assigned to a company or organization that participates in financial markets, like a corporate passport number. It helps investors and regulators unambiguously identify counterparties across databases and transactions, reducing confusion much like using a vehicle identification number to track a car’s history; clearer identification improves transparency, risk monitoring, and regulatory reporting.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When was the AstraZeneca (AZN) chair’s transaction reported?
AstraZeneca states it was notified on September 14, 2026 of the purchase, which occurred that same day. The Form 6-K recording the Director/PDMR shareholding is dated September 15, 2026.
Under which regulation was the AZN PDMR transaction disclosed?
The transaction was notified in accordance with the EU Market Abuse Regulation, as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.
AI-generated analysis. How Rhea-AI works. Not financial advice.
